Skip to main content
Terug
BWAY logo

BrainsWay Ltd.

Datakwaliteit: 100%
BWAY
NASDAQ Healthcare Medical - Devices
€ 13,71
▲ € 0,05 (0,37%)
Marktkapitalisatie: 537,75M
Dagbereik
€ 12,88 € 13,99
52-Weeksbereik
€ 3,92 € 14,65
Volume
272.542
50D / 200D Gem.
€ 12,15 / € 8,61
Vorige Slotkoers
€ 13,66

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 69,9 0,4
P/B 7,3 2,9
ROE % 11,4 3,7
Net Margin % 14,6 3,9
Rev Growth 5Y % 15,4 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 30,00 +118.8%
Forward K/W
70,3
Forward WPA
€ 0,20
WPA Groei (sch.)
+0,0%
Omzet Sch.
66 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2028 € 0,28
€ 0,27 – € 0,29
110 M 1
FY2027 € 0,28
€ 0,20 – € 0,39
81 M 3
FY2026 € 0,20
€ 0,16 – € 0,26
66 M 3

Belangrijkste Punten

Revenue grew 15,42% annually over 5 years — strong growth
Earnings grew 163,39% over the past year
ROE of 11,35% — decent returns on equity
Debt/Equity of 0,09 — conservative balance sheet
Generating 16,40M in free cash flow
P/E of 69,90 — premium valuation

Groei

Revenue Growth (5Y)
15,42%
Revenue (1Y)28,34%
Earnings (1Y)163,39%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
11,35%
ROIC4,08%
Net Margin14,62%
Op. Margin8,28%

Veiligheid

Debt / Equity
0,09
Current Ratio3,83
Interest Coverage1,96

Waardering

P/E Ratio
69,90
P/B Ratio7,34
EV/EBITDA109,38
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 28,34% Revenue Growth (3Y) 28,69%
Earnings Growth (1Y) 163,39% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 15,42% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 52,64M Net Income (TTM) 7,69M
ROE 11,35% ROA 6,81%
Gross Margin 75,42% Operating Margin 8,28%
Net Margin 14,62% Free Cash Flow (TTM) 16,40M
ROIC 4,08% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,09 Current Ratio 3,83
Interest Coverage 1,96 Dividend Yield 0,00%
Valuation
P/E Ratio 69,90 P/B Ratio 7,34
P/S Ratio 10,22 PEG Ratio 0,06
EV/EBITDA 109,38 Dividend Yield 0,00%
Market Cap 537,75M Enterprise Value 476,61M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 52,64M 41,02M 31,79M 27,18M 29,66M
Net Income 7,69M 2,92M -4,20M -13,35M -6,46M
EPS (Diluted) 0,36 0,09 -0,13 -0,43 -0,21
Gross Profit 39,70M 30,58M 23,48M 20,05M 23,06M
Operating Income 4,36M 1,39M -4,96M -12,68M -5,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 112,92M 94,32M 62,97M 64,48M 75,73M
Total Liabilities 34,67M 32,00M 21,39M 19,08M 18,41M
Shareholders' Equity 73,22M 62,31M 41,58M 45,40M 57,33M
Total Debt 6,82M 5,62M 471.000,0 488.000,0 754.000,0
Cash & Equivalents 67,95M 69,35M 10,52M 47,58M 16,92M
Current Assets 84,89M 79,67M 55,47M 58,09M 65,45M
Current Liabilities 22,16M 15,35M 9,76M 8,14M 9,07M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
#776 of 1024
32
Custom Full Throttle
#144 of 146
7

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026